Curaleaf Holdings (CURLF) Cash from Financing Activities (2019 - 2024)

Curaleaf Holdings (CURLF) posted quarterly Cash from Financing Activities of -$6.6 million for Q4 2024, up 61.27% year-on-year from -$4.1 million in Q1 2024, and up 46.11% on a QoQ basis from -$12.2 million in Q3 2024.

Curaleaf Holdings (CURLF) Cash from Financing Activities (2019 - 2024) Analysis & Trends

Curaleaf Holdings (CURLF) has reported Cash from Financing Activities for 6 consecutive years, with -$6.6 million the latest figure, recorded in Q4 2024.

  • Quarterly Cash from Financing Activities rose 61.27% year-over-year to -$6.6 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$54.1 million (up 19.26% YoY) and the FY2025 annual result came in at -$73.5 million, down 35.86% from the prior year.
  • Cash from Financing Activities advanced to -$6.6 million in Q4 2024 per CURLF's latest filing, from -$12.2 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for CURLF reached as high as $28.6 billion in Q2 2023 and fell as low as -$28.6 billion in Q1 2023.
  • A 5-year average of $27.4 million and a median of $1.7 million in 2020 frame the typical range for Cash from Financing Activities.
  • The largest YoY upside for Cash from Financing Activities was 59634.52% in 2023 against a maximum downside of 171254.23% in 2023.
  • Year by year, Cash from Financing Activities stood at $3.4 million in 2020, then soared by 2674.62% to $95.2 million in 2021, then tumbled by 59.54% to $38.5 million in 2022, then sank by 144.09% to -$17.0 million in 2023, then surged by 61.27% to -$6.6 million in 2024.
  • According to Business Quant data, Cash from Financing Activities over the past three periods registered -$6.6 million, -$12.2 million, and -$15.7 billion for Q4 2024, Q3 2024, and Q2 2024 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 13.00 Mn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn -840.00 Mn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -494.13 Mn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn -1.48 Bn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn -203.80 Mn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn -86.10 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn -65.00 Mn
10 Curaleaf Holdings 7.13 Bn 7.13 Bn 157.29 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2024 -6.58 Mn
Dec 31, 2024 -6.58 Mn
Sep 30, 2024 -12.21 Mn
Sep 30, 2024 -12.21 Mn
Jun 30, 2024 -15.73 Bn
Jun 30, 2024 -15.73 Bn
Mar 31, 2024 15.70 Bn
Mar 31, 2024 15.70 Bn
Dec 31, 2023 -16.99 Mn
Dec 31, 2023 -16.99 Mn
Sep 30, 2023 5.06 Mn
Sep 30, 2023 5.06 Mn
Jun 30, 2023 28.59 Bn
Jun 30, 2023 28.59 Bn
Mar 31, 2023 -28.65 Bn
Mar 31, 2023 -28.65 Bn
Dec 31, 2022 38.53 Mn
Dec 31, 2022 38.53 Mn
Sep 30, 2022 -27.89 Mn
Sep 30, 2022 -27.89 Mn